Timothy A. Chan
Timothy Chan showed that tumour mutational burden predicts who benefits from checkpoint inhibitors.
Physician-scientist whose 2014 and 2015 genomic studies linked mutational load and neoantigens to response to CTLA-4 and PD-1 blockade, and who showed HLA diversity shapes immunotherapy benefit.
| Title | Journal | Year |
|---|---|---|
| Genetic basis for clinical response to CTLA-4 blockade in melanoma | New England Journal of Medicine | 2014 |
| Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer | Science | 2015 |
Pages like this
not linked directly; found by shared links- PersonNathan A. Pennell
Shares Cleveland Clinic Taussig Cancer Institute, Non-small-cell lung cancer.
- PersonRamaswamy Govindan
Shares Tumour mutational burden (TMB), Non-small-cell lung cancer.
- PersonRobert D. Schreiber
Shares Neoantigen, Immune checkpoint inhibitors.
- PersonKellie N. Smith
Shares Neoantigen, Immune checkpoint inhibitors.
- Key paperKEYNOTE-942: a personalised mRNA cancer vaccine plus pembrolizumab after melanoma surgery
Shares Tumour mutational burden (TMB), Neoantigen, Melanoma, Immune checkpoint inhibitors.
- InstitutionLausanne University Hospital (CHUV) / Ludwig Institute Lausanne
Shares Neoantigen, Melanoma, Immune checkpoint inhibitors, Non-small-cell lung cancer.
- PersonAurélien Marabelle
Shares Tumour mutational burden (TMB), Immune checkpoint inhibitors.
- InstitutionLeiden University Medical Center
Shares Neoantigen, Melanoma, Immune checkpoint inhibitors.